Use of amphotericin B in immunosuppressed patients with cancer. Part Two: Pharmacodynamics and nursing implications.
Nursing care of patients receiving amphotericin B (AmB) must address the underlying condition of the immunosuppressed patient with cancer and the iatrogenic responses induced by the drug. This review, the companion to "Part One: Pharmacology and Toxicities," focuses on nursing actions that consider both the drug's specific pharmacodynamics and the altered human responses caused by disease and therapy. Maximization of drug effectiveness and minimization of drug toxicity are key care goals.
Holtzclaw
B J
BJ
Vanderbilt University School of Nursing, Nashville, TN.
Rutledge
D N
DN
D000666:Amphotericin B / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004344:Drug Incompatibility; D004347:Drug Interactions; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing; D009369:Neoplasms / Q000150:complications*; D010347:Patient Care Planning
D000666:Amphotericin B